...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: Resverlogix’ BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events

Bear so does this seem that all data will be announced all at once?

And "acute coronary syndrome" one of the 3 indications that Resverlogix will be focusing on, would this be one and the same that went on in 2015 with the Clevland clinic, "ASSURE" trial?

 

Koo

 

Share
New Message
Please login to post a reply